Vascugenix Prepares to Launch Speed-Torque Device: Designed to Improve the Process of Guidewire Manipulation in Cardiovascular Procedures

Vascugenix is a medical device company focused on developing innovative products to improve interventional cardiovascular procedures, is preparing to launch its first developed device, the Speed-Torque, in the U.S. market.

Vascugenix notes the Speed-Torque is specially designed to improve the process of guidewire manipulation in cardiovascular procedures. The patented design allows physicians to easily manipulate a guidewire with one hand, unlike traditional guidewire torque devices that require two hands to advance and reposition.

The Vascugenix team partnered with Gilero, a medical device design, development, and manufacturing company, to take this novel product idea from concept to commercialization.

“Vascugenix has worked closely with Gilero over the past nine months to develop and commercialize the Speed-Torque. Bringing a new device to the market during the COVID pandemic has been challenging, but Gilero and Vascugenix have worked closely together to make it happen,” says Martial Trigeaud, Chief Operating Officer for Vascugenix.

“Thanks to the dedication of Gilero, as well their Shenzhen-based injection molding partner Medacys, we were able to fully develop this device and bring it to market in a relatively short period of time,” adds Trigeaud. “The team at Vascugenix is excited to bring this product to market. The Speed-Torque will ultimately save physicians time, hospitals money, and improve patient safety.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version